Literature DB >> 27698863

Promoter methylation and downregulated expression of the TBX15 gene in ovarian carcinoma.

Gaia Gozzi1, Sonia T Chelbi2, Paola Manni3, Loredana Alberti4, Sergio Fonda3, Sara Saponaro1, Luca Fabbiani5, Francesco Rivasi5, Jean Benhattar6, Lorena Losi3.   

Abstract

TBX15 is a gene involved in the development of mesodermal derivatives. As the ovaries and the female reproductive system are of mesodermal origin, the aim of the present study was to determine the methylation status of the TBX15 gene promoter and the expression levels of TBX15 in ovarian carcinoma, which is the most lethal and aggressive type of gynecological tumor, in order to determine the role of TBX15 in the pathogenesis of ovarian carcinoma. This alteration could be used to predict tumor development, progression, recurrence and therapeutic effects. The study was conducted on 80 epithelial ovarian carcinoma and 17 control cases (normal ovarian and tubal tissues). TBX15 promoter methylation was first determined by pyrosequencing following bisulfite modification, then by cloning and sequencing, in order to obtain information about the epigenetic haplotype. Immunohistochemical analysis was performed to evaluate the correlation between the methylation and protein expression levels. Data revealed a statistically significant increase of the TBX15 promoter region methylation in 82% of the tumor samples and in various histological subtypes. Immunohistochemistry showed an inverse correlation between methylation levels and the expression of the TBX15 protein. Furthermore, numerous tumor samples displayed varying degrees of intratumor heterogeneity. Thus, the present study determined that ovarian carcinoma typically expresses low levels of TBX15 protein, predominantly due to an epigenetic mechanism. This may have a role in the pathogenesis of ovarian carcinoma independent of the histological subtype.

Entities:  

Keywords:  DNA methylation; TBX15; epigenetics; immunohistochemistry; ovarian carcinoma; pyrosequencing

Year:  2016        PMID: 27698863      PMCID: PMC5038588          DOI: 10.3892/ol.2016.5019

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

Review 1.  T-box genes in early embryogenesis.

Authors:  Chris Showell; Olav Binder; Frank L Conlon
Journal:  Dev Dyn       Date:  2004-01       Impact factor: 3.780

2.  Tbx3 expression is related to apoptosis and cell proliferation in rat bladder both hyperplastic epithelial cells and carcinoma cells.

Authors:  Aya Ito; Makoto Asamoto; Naomi Hokaiwado; Satoru Takahashi; Tomoyuki Shirai
Journal:  Cancer Lett       Date:  2005-02-28       Impact factor: 8.679

3.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

Review 4.  Regulation of organogenesis and stem cell properties by T-box transcription factors.

Authors:  Yasuo Takashima; Atsushi Suzuki
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 5.  Epigenetic biomarkers in epithelial ovarian cancer.

Authors:  Brian S Gloss; Goli Samimi
Journal:  Cancer Lett       Date:  2012-01-12       Impact factor: 8.679

6.  BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells.

Authors:  Debalina Sarkar; Brian Shields; Melanie L Davies; Jürgen Müller; Jane A Wakeman
Journal:  Int J Cancer       Date:  2011-05-28       Impact factor: 7.396

7.  Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA.

Authors:  Cathy B Moelans; Jolien S de Groot; Xiaojuan Pan; Elsken van der Wall; Paul J van Diest
Journal:  Mod Pathol       Date:  2013-11-29       Impact factor: 7.842

Review 8.  The role of Tbx2 and Tbx3 in mammary development and tumorigenesis.

Authors:  Matthew Rowley; Erin Grothey; Fergus J Couch
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-04       Impact factor: 2.673

9.  T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma.

Authors:  Ikumi Imajyo; Tsuyoshi Sugiura; Yosuke Kobayashi; Miyuki Shimoda; Kotaro Ishii; Naonari Akimoto; Naoya Yoshihama; Ieyoshi Kobayashi; Yoshihide Mori
Journal:  Int J Oncol       Date:  2012-10-17       Impact factor: 5.650

10.  Expression of the Brachyury gene during mesoderm development in differentiating embryonal carcinoma cell cultures.

Authors:  G Vidricaire; K Jardine; M W McBurney
Journal:  Development       Date:  1994-01       Impact factor: 6.868

View more
  6 in total

1.  Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data.

Authors:  Xin Zhou; Zhibin Chen; Xiaodong Cai
Journal:  Epigenetics       Date:  2018-08-07       Impact factor: 4.528

2.  Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.

Authors:  Lorena Losi; Sergio Fonda; Sara Saponaro; Sonia T Chelbi; Cesare Lancellotti; Gaia Gozzi; Loredana Alberti; Luca Fabbiani; Laura Botticelli; Jean Benhattar
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

Review 3.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

4.  Transcriptome profiling of lncRNA and co-expression network in the vaginal epithelial tissue of women with lubrication disorders.

Authors:  Jingjing Zhang; Jing Zhang; Shengnan Cong; Jingyi Feng; Lianjun Pan; Yuan Zhu; Aixia Zhang; Jiehua Ma
Journal:  PeerJ       Date:  2021-11-10       Impact factor: 2.984

Review 5.  Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Cancer Drug Resist       Date:  2019-06-19

6.  TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma.

Authors:  Gabija JuknytĖ; Inga LaurinaitytĖ; Alvita VilkeviČiŪtĖ; Greta GedvilaitĖ; Brigita GlebauskienĖ; Loresa KriauČiŪnienĖ; Rasa LiutkeviČienĖ
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.